Disrupting the p53-mdm2 interaction as a potential therapeutic modality

Ute M. Moll, Alexander Zaika

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalDrug Resistance Updates
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Ubiquitin
Neoplasms
Proteins
Therapeutics
ATP dependent 26S protease

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Disrupting the p53-mdm2 interaction as a potential therapeutic modality. / Moll, Ute M.; Zaika, Alexander.

In: Drug Resistance Updates, Vol. 3, No. 4, 01.01.2000, p. 217-221.

Research output: Contribution to journalArticle

@article{4534da7b9d0c482eb6aba14f84972159,
title = "Disrupting the p53-mdm2 interaction as a potential therapeutic modality",
abstract = "P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.",
author = "Moll, {Ute M.} and Alexander Zaika",
year = "2000",
month = "1",
day = "1",
doi = "10.1054/drup.2000.0160",
language = "English (US)",
volume = "3",
pages = "217--221",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Disrupting the p53-mdm2 interaction as a potential therapeutic modality

AU - Moll, Ute M.

AU - Zaika, Alexander

PY - 2000/1/1

Y1 - 2000/1/1

N2 - P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.

AB - P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0033835043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033835043&partnerID=8YFLogxK

U2 - 10.1054/drup.2000.0160

DO - 10.1054/drup.2000.0160

M3 - Article

AN - SCOPUS:0033835043

VL - 3

SP - 217

EP - 221

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 4

ER -